Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.

To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer protection from HIV infection. While encouraging, the modest 31.2% (P = 0.04) efficacy achieved in this study left significant room for improvement, and created an incentive to optimize the AIDSVAX B/E...

Full description

Bibliographic Details
Main Authors: Rachel C Doran, Gwen P Tatsuno, Sara M O'Rourke, Bin Yu, David L Alexander, Kathryn A Mesa, Phillip W Berman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5916523?pdf=render

Internet

http://europepmc.org/articles/PMC5916523?pdf=render

Similar Items